Biogen (BIIB) PT Lowered to $360 at BofA Securities as Alzheimer's Realities Come Into Focus
Tweet Send to a Friend
BofA Securities analyst Geoff Meacham lowered the price target on Biogen (NASDAQ: BIIB) to $360.00 (from $400.00) on continued fallout ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
